The newest COVID-19 vaccine candidate to start human testing is the first where volunteers won’t get a painful injection. Instead, they’ll receive a spray through the nose.
China on Wednesday approved phase one human testing for the nasal spray vaccine, which is co-developed by researchers at Xiamen University and Hong Kong University, as well as by vaccine maker Beijing Wantai Biological Pharmacy Enterprise Co.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.